Relief Therapeutics Holding SA (SWX:RLF)
Switzerland
· Delayed Price · Currency is CHF 2.230
-0.030 (-1.33%)
Apr 4, 2025, 10:10 AM CET
SWX:RLF Revenue
Relief Therapeutics Holding had revenue of 3.01M CHF in the half year ending December 31, 2023, a decrease of -9.36%. This brings the company's revenue in the last twelve months to 8.60M, up 45.04% year-over-year. In the year 2023, Relief Therapeutics Holding had annual revenue of 6.03M, down -0.79%.
Revenue (ttm)
8.60M
Revenue Growth
+45.04%
P/S Ratio
3.28
Revenue / Employee
175.47K
Employees
49
Market Cap
28.34M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.40B |
| Novartis AG | 46.87B |
| Alcon | 8.98B |
| Lonza Group AG | 6.57B |
| Galderma Group AG | 4.02B |
| Straumann Holding AG | 2.50B |
| Sandoz Group AG | 9.41B |
| Sonova Holding AG | 3.71B |
Relief Therapeutics Holding News
- 4 weeks ago - Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion - Accesswire
- 7 weeks ago - Relief Therapeutics to get European patent for investigational drug RLF‑TD011 - Seeking Alpha
- 7 weeks ago - Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 - Accesswire
- 2 months ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 2 months ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 3 months ago - Relief Therapeutics advances merger talks with Renexxion - Seeking Alpha
- 3 months ago - Relief Therapeutics Provides Update on Potential Transaction with Renexxion - Accesswire
- 3 months ago - Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial - Accesswire